Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.
This application is a continuation of U.S. application Ser. No. 11/241,700, filed Sep. 29, 2005, now U.S. Pat. No. 7,202,262 which is a continuation of U.S. application Ser. No. 10/822,259, filed Apr. 9, 2004, now U.S. Pat. No. 6,992,096, which claims the benefit of U.S. Provisional Application No. 60/461,988, filed Apr. 11, 2003, each application being incorporated by reference herein in its entirety.
